计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| V126681-10mg |
10mg |
现货 ![]() |
| |
| V126681-25mg |
25mg |
现货 ![]() |
| |
| V126681-50mg |
50mg |
现货 ![]() |
| |
| V126681-100mg |
100mg |
现货 ![]() |
| |
| V126681-250mg |
250mg |
现货 ![]() |
|
| 英文别名 | BCPP000015 | s1458 | BRD-K91900765-001-01-9 | Kinome_3767 | 5-(2,6-dichlorophenyl)-2-[(2,4-difluorophenyl)thio]pyrimido[1,6-b]pyridazin-6-one | 5-(2,6-dichlorophenyl)-2-(2,4-difluorophenyl)sulfanylpyrimido[1,6-b]pyridazin-6-one | 5T-0205 | CCG-269082 | AC |
|---|---|
| 规格或纯度 | Moligand™, ≥98% |
| 英文名称 | VX-745 |
| 生化机理 | VX-745 是一种高效、选择性的 p38α 抑制剂(IC50 = 10 nM)。VX-745 还能阻止体外 LPS 刺激的 HWB 产生 TNFα(IC50 = 177 nM)。VX-745 对 ERK1、MK2 和 JNK1-3 等密切相关的激酶具有 1000 倍的选择性。VX-745 是一种强效、选择性 p38 alpha\xa0MAPK 抑制剂(IC50 = 10 nM),对 p38 beta\xa0 的选择性为 20 倍,对密切相关的激酶 ERK1 和 JNK1-3 的选择性为 1000 倍。VX-745 对 p38α 的选择性是 p38β 的 20 倍,Ki 值为 220 nM。研究表明,VX-745 可减轻关节炎(AIA)小鼠模型的炎症反应,并可改善老年大鼠的表现。 |
| 储存温度 | 避光,-20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 抑制剂 |
| 作用机制 | MAP 激酶 p38 alpha 抑制剂 |
| 备注 | 需要更多关于溶解度,用法和处理的建议吗?请访问我们的常见问题(FAQ)页面以获取更多详细信息。 |
| 产品介绍 |
Neflamapimod (VX-745) 是有效的,可穿过血脑屏障的,高选择性的 p38α 抑制剂,对 p38α 的 IC50 值为 10 nM,p38β 的 IC50 值为 220 nM。Neflamapimod (VX-745) 具有抗炎活性。 |
| 纯度 | ≥98% |
| ALogP | 5.1 |
|---|
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| PubChem SID | 504762373 |
|---|---|
| 分子类型 | 小分子 |
| IIUPAC Name | 5-(2,6-dichlorophenyl)-2-(2,4-difluorophenyl)sulfanylpyrimido[1,6-b]pyridazin-6-one |
| INCHI | 1S/C19H9Cl2F2N3OS/c20-11-2-1-3-12(21)17(11)18-14-5-7-16(25-26(14)9-24-19(18)27)28-15-6-4-10(22)8-13(15)23/h1-9H |
| InChi Key | VEPKQEUBKLEPRA-UHFFFAOYSA-N |
| Smiles | C1=CC(=C(C(=C1)Cl)C2=C3C=CC(=NN3C=NC2=O)SC4=C(C=C(C=C4)F)F)Cl |
| Isomeric SMILES | C1=CC(=C(C(=C1)Cl)C2=C3C=CC(=NN3C=NC2=O)SC4=C(C=C(C=C4)F)F)Cl |
| PubChem CID | 3038525 |
| 分子量 | 436.27 |
| 溶解性 | DMSO ≥60mg/mL Water <1.2mg/mL Ethanol <1.2mg/mL;Chloroform, DMSO, Methanol |
|---|---|
| 敏感性 | 对光敏感 |
| 熔点 | 259-262°C (dec.) |
| 分子量 | 436.300 g/mol |
| XLogP3 | 5.100 |
| 氢键供体数Hydrogen Bond Donor Count | 0 |
| 氢键受体数Hydrogen Bond Acceptor Count | 5 |
| 可旋转键计数Rotatable Bond Count | 3 |
| 精确质量Exact Mass | 434.981 Da |
| 单同位素质量Monoisotopic Mass | 434.981 Da |
| 拓扑极表面积Topological Polar Surface Area | 70.300 Ų |
| 重原子数Heavy Atom Count | 28 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 762.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 0 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
| 1. Fitzgerald CE, Patel SB, Becker JW, Cameron PM, Zaller D, Pikounis VB, O'Keefe SJ, Scapin G. (2003) Structural basis for p38alpha MAP kinase quinazolinone and pyridol-pyrimidine inhibitor specificity.. Nat Struct Biol, 10 (9): (764-9). [PMID:12897767] |
| 2. Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, Campbell BT, Chan KW, Ciceri P, Davis MI, Edeen PT et al.. (2008) A quantitative analysis of kinase inhibitor selectivity.. Nat Biotechnol, 26 (1): (127-32). [PMID:18183025] |
| 3. Munoz L, Ralay Ranaivo H, Roy SM, Hu W, Craft JM, McNamara LK, Chico LW, Van Eldik LJ, Watterson DM. (2007) A novel p38 alpha MAPK inhibitor suppresses brain proinflammatory cytokine up-regulation and attenuates synaptic dysfunction and behavioral deficits in an Alzheimer's disease mouse model.. J Neuroinflammation, 4 (21). [PMID:17784957] |
| 4. Duffy JP, Harrington EM, Salituro FG, Cochran JE, Green J, Gao H, Bemis GW, Evindar G, Galullo VP, Ford PJ et al.. (2011) The Discovery of VX-745: A Novel and Selective p38α Kinase Inhibitor.. ACS Med Chem Lett, 2 (10): (758-63). [PMID:24900264] |
| 5. Alam JJ. (2015) Selective Brain-Targeted Antagonism of p38 MAPKα Reduces Hippocampal IL-1β Levels and Improves Morris Water Maze Performance in Aged Rats.. J Alzheimers Dis, 48 (1): (219-27). [PMID:26401942] |
| 6. Alam J, Blackburn K, Patrick D. (2017) Neflamapimod: Clinical Phase 2b-Ready Oral Small Molecule Inhibitor of p38α to Reverse Synaptic Dysfunction in Early Alzheimer's Disease.. J Prev Alzheimers Dis, 4 (4): (273-278). [PMID:29181493] |